• Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
Quantisnow Logo
  • Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
PublishGo to App
    Quantisnow Logo

    © 2026 quantisnow.com
    Democratizing insights since 2022

    Services
    Live news feedsRSS FeedsAlertsPublish with Us
    Company
    AboutQuantisnow PlusContactJobsAI superconnector for talent & startupsNEWLLM Arena
    Legal
    Terms of usePrivacy policyCookie policy

    morph Launches the World's First Shapeshifting Soft Robotics Cells Platform to Bring Physical AI into Real-World Applications

    6/2/26 6:00:00 AM ET
    $MDT
    Biotechnology: Electromedical & Electrotherapeutic Apparatus
    Health Care
    Get the next $MDT alert in real time by email

    Backed by 8VC, Pharrell Williams, Copper, Harvey Spevak of Equinox Group, Qubit Ventures, Valia Ventures, and Blue Lion

    morph today launches a physically intelligent soft robotics platform that designs and manufactures what it calls "soft robotic cells," a term coined by the company. Founded by Dr. Jean Nehme, a former reconstructive surgeon who founded and exited surgical AI company Digital Surgery, morph's soft robotics platform marks a new frontier in physical AI and next-generation robotics by embedding sensing and adaptive control directly into reconfigurable deformable materials, enabling real‑time change in morphology and stiffness. morph is helping define a new category of embodied AI: intelligence built directly into physical products so they can sense, adapt, and respond in real time. Physical AI is not just a software problem — it is a hardware problem as well, and the two must work in tandem. Soft robotic cells can be placed into multiple products to better respond to human movement and interaction, representing a shift from static, hard consumer and enterprise B2B product solutions to adaptive, responsive systems. In practice, this means moving from passive products to products that deliver responsive support and services through the materials themselves.

    This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260602211043/en/

    The company also announced that 8VC, Pharrell Williams, Copper, Harvey Spevak, Chairman of Equinox Group, Qubit Health Capital, Valia Ventures, Blue Lion have invested in morph.

    Born from Clinical Experience, Built for Real Life

    morph founder Dr. Jean Nehme, a former reconstructive surgeon, understands from operating on the human body the softness of biology and has modelled soft robotic cells on this. Furthermore, Jean also understands how small biomechanical inefficiencies compound over the years, quietly degrading mobility and impacting long-term health.

    "We have designed and built a very rigid and static world, but since the beginning nature has shown us softness and dynamism," said Dr. Jean Nehme, Founder of morph. "With our platform, we can build a new generation of products embedded with soft robotic cells that adapt in real time to support natural movement. We're designing soft robotic cells to sit at the interface of human robotic interaction across multiple industries."

    Dr. Nehme founded morph with a global team of experts in design, AI, robotics, medicine, and manufacturing, chosen for their expertise in biology and movement. Previously, Dr. Nehme was founder and CEO of Digital Surgery, a pioneer in surgical AI and computer vision, data and analytics, and digital education and training. Medtronic (NYSE:MDT) acquired the company in 2020. Dr. Nehme has been building in AI since 2013, bringing a long-standing background in applying intelligence to high-stakes real-world environments. His track record combines surgeon-led precision with deep expertise in AI, positioning morph to bring soft robotic cells to consumers and industry partners.

    Introducing Soft Robotics with Shapeshifting Cells: Designed for the Human Experience

    Soft robotics is a class of robotics, built from flexible, deformable soft robotic cells. Unlike traditional rigid robotics built for industrial environments, soft robots are based on soft deformable materials, which means it can enable safer interaction with humans. morph further advances this category with soft robotic cells that shapeshift - modular robotic units made of synthetic materials that process environmental and user information and change their morphology to achieve specific objectives. These cells embed intelligence directly into materials, enabling products to sense, adapt, and respond to the body and the environment in real time. In other words, embodied AI is not just software that advises, it is intelligence built into physical systems that can take action through the product itself. Soft robotic cells can be configured into combinations across multiple product lines and generate data sets that enable richer human-physical world interactions.

    morph is developing a pipeline of applications that embed their soft robotic cells, each designed to redefine its category by replacing static materials with adaptive systems. Their first applications will be built to fuel human performance, movement, and longevity. Initial applications will include athletic performance, injury prevention, and mobility support. Over time, the programmable platform will scale across categories, including healthcare, automotive, and industrial safety, positioning morph at the intersection of soft robotics and the rapidly expanding physical AI market, enabling a connected ecosystem of adaptive performance systems to improve human health. morph is partnering with multiple industrial partners at this stage. With morph's B2B strategy, the goal is to operate as a software, design, and fabrication partner, working with industries and companies to enable them with soft robotics technology.

    Inspired by the adaptability of octopuses, morph is accelerating the development of physical AI systems. morph's modular platform empowers teams to program robotic cell behaviors, simulate real-world conditions, and rapidly iterate soft, deformable components built for direct human interaction. By integrating reinforcement learning with high-fidelity physics-based simulation, morph enables a faster translation from concept to product without sacrificing clinical rigor or safety. The result is a platform designed not only to advance robotics technically, but to make adaptive, responsive products more useful in everyday life.

    About morph

    morph is building the world's first soft robotics platform. Driven by a worldwide team of experts in robotics, AI, medicine, design, and manufacturing, morph enables the creation of products that embed robotic cells. Initial product offerings will focus on human performance and longevity. To learn more, please visit www.morph.inc.

    View source version on businesswire.com: https://www.businesswire.com/news/home/20260602211043/en/

    morph@aiir.agency

    Get the next $MDT alert in real time by email

    Crush Q1 2026 with the Best AI Superconnector

    Stay ahead of the competition with Standout.work - your AI-powered talent-to-startup matching platform.

    AI-Powered Inbox
    Context-aware email replies
    Strategic Decision Support
    Get Started with Standout.work

    Recent Analyst Ratings for
    $MDT

    DatePrice TargetRatingAnalyst
    5/21/2026$84.00Neutral
    Goldman
    2/13/2026$116.00Overweight
    Barclays
    2/9/2026$121.00Hold → Buy
    Needham
    2/3/2026$117.00Buy
    Citigroup
    1/30/2026$114.00Overweight
    Wells Fargo
    1/6/2026Mkt Perform → Outperform
    William Blair
    11/19/2025$111.00Sell → Neutral
    Goldman
    6/30/2025Underperform → Peer Perform
    Wolfe Research
    More analyst ratings

    $MDT
    Analyst Ratings

    Analyst ratings in real time. Analyst ratings have a very high impact on the underlying stock. See them live in this feed.

    View All

    Goldman resumed coverage on Medtronic with a new price target

    Goldman resumed coverage of Medtronic with a rating of Neutral and set a new price target of $84.00

    5/21/26 8:09:17 AM ET
    $MDT
    Biotechnology: Electromedical & Electrotherapeutic Apparatus
    Health Care

    Barclays resumed coverage on Medtronic with a new price target

    Barclays resumed coverage of Medtronic with a rating of Overweight and set a new price target of $116.00

    2/13/26 8:31:53 AM ET
    $MDT
    Biotechnology: Electromedical & Electrotherapeutic Apparatus
    Health Care

    Medtronic upgraded by Needham with a new price target

    Needham upgraded Medtronic from Hold to Buy and set a new price target of $121.00

    2/9/26 6:45:10 AM ET
    $MDT
    Biotechnology: Electromedical & Electrotherapeutic Apparatus
    Health Care

    $MDT
    SEC Filings

    View All

    Medtronic plc. filed SEC Form 8-K: Results of Operations and Financial Condition, Financial Statements and Exhibits

    8-K - Medtronic plc (0001613103) (Filer)

    6/3/26 6:47:08 AM ET
    $MDT
    Biotechnology: Electromedical & Electrotherapeutic Apparatus
    Health Care

    SEC Form SD filed by Medtronic plc.

    SD - Medtronic plc (0001613103) (Filer)

    5/28/26 4:11:12 PM ET
    $MDT
    Biotechnology: Electromedical & Electrotherapeutic Apparatus
    Health Care

    Medtronic plc. filed SEC Form 8-K: Leadership Update, Financial Statements and Exhibits

    8-K - Medtronic plc (0001613103) (Filer)

    5/18/26 4:30:33 PM ET
    $MDT
    Biotechnology: Electromedical & Electrotherapeutic Apparatus
    Health Care

    $MDT
    Insider Trading

    Insider transactions reveal critical sentiment about the company from key stakeholders. See them live in this feed.

    View All

    SVP, Chief HR Officer Walter Matthew R. converted options into 9,149 units of Ordinary Shares, increasing direct ownership by 28% to 41,529 units (SEC Form 4)

    4 - Medtronic plc (0001613103) (Issuer)

    5/28/26 4:26:58 PM ET
    $MDT
    Biotechnology: Electromedical & Electrotherapeutic Apparatus
    Health Care

    EVP & Pres Neuroscience Wall Brett A. converted options into 26,907 units of Ordinary Shares, increasing direct ownership by 49% to 82,183 units (SEC Form 4)

    4 - Medtronic plc (0001613103) (Issuer)

    5/28/26 4:26:23 PM ET
    $MDT
    Biotechnology: Electromedical & Electrotherapeutic Apparatus
    Health Care

    Chairman and CEO Martha Geoffrey converted options into 94,963 units of Ordinary Shares, increasing direct ownership by 38% to 343,099 units (SEC Form 4)

    4 - Medtronic plc (0001613103) (Issuer)

    5/28/26 4:25:58 PM ET
    $MDT
    Biotechnology: Electromedical & Electrotherapeutic Apparatus
    Health Care

    $MDT
    Press Releases

    Fastest customizable press release news feed in the world

    View All

    Medtronic submits 510(k) filings to expand Hugo™ robotic-assisted surgery system into general and gynecologic specialties in the United States

    Company also announces 510(k) pending for LigaSure™ RAS Maryland instrument on the Hugo RAS system, and 510(k) clearance for ProGrip™ Advanced self-gripping polypropylene mesh for use in robotic-assisted ventral hernia repair surgeriesGALWAY, Ireland, June 3, 2026 /PRNewswire/ -- Medtronic (NYSE:MDT), a global leader in healthcare technology, today announced significant milestones to unlock expanded indications for the Hugo™ robotic-assisted surgery (RAS) system in the United States and to shape the future of surgery.General surgery indication including hernia repair — 510(k) clearance submittedEmbrace Gynecology Investigational Device Exemption (IDE) clinical study — completed enrollmentGyn

    6/3/26 7:05:00 AM ET
    $MDT
    Biotechnology: Electromedical & Electrotherapeutic Apparatus
    Health Care

    Medtronic announces strategic investments to support future expansion of cardiac ablation portfolio as physician demand for Affera™ technologies broadens

    Investments in intracardiac echocardiography (ICE) technologies highlight Medtronic's commitment to driving durable growth in the cardiac ablation business through a differentiated portfolio of technologiesGALWAY, Ireland, June 3, 2026 /PRNewswire/ -- Medtronic plc (NYSE:MDT), a global leader in healthcare technology, today announced strategic investments in two privately held companies focused on the development of intracardiac echocardiography (ICE) catheter technologies. ICE catheters provide real-time, high-resolution imaging of the heart during electrophysiology (EP) procedures for cardiac arrhythmias such as atrial fibrillation (Afib). Medtronic intends to integrate ICE into the Affera

    6/3/26 6:55:00 AM ET
    $MDT
    Biotechnology: Electromedical & Electrotherapeutic Apparatus
    Health Care

    Medtronic reports fourth quarter and full year fiscal 2026 results; delivers highest annual revenue growth in 10 years

    Disciplined execution and portfolio strength position Medtronic for continued momentum into fiscal year 2027GALWAY, Ireland, June 3, 2026 /CNW/ -- Medtronic plc (NYSE:MDT), a global leader in healthcare technology, today announced financial results for its fourth quarter (Q4) and fiscal year 2026 (FY26), which ended April 24, 2026.Q4 Key HighlightsRevenue of $9.8 billion, increased 9.9% as reported and 6.6% organic, 90 basis points ahead of Q4 implied guidanceGAAP diluted EPS of $0.96; non-GAAP diluted EPS of $1.55, ahead of guidanceCardiac Ablation Solutions revenue increased 78% globally, including 124% U.S. growth, gaining an additional 8 points of U.S. shareCardiovascular grew 10.1%, led

    6/3/26 6:45:00 AM ET
    $MDT
    Biotechnology: Electromedical & Electrotherapeutic Apparatus
    Health Care

    $MDT
    Insider Purchases

    Insider purchases reveal critical bullish sentiment about the company from key stakeholders. See them live in this feed.

    View All

    Director Jellison William R bought $462,750 worth of Ordinary Shares (5,000 units at $92.55) (SEC Form 4)

    4 - Medtronic plc (0001613103) (Issuer)

    8/25/25 5:18:06 PM ET
    $MDT
    Biotechnology: Electromedical & Electrotherapeutic Apparatus
    Health Care

    $MDT
    Large Ownership Changes

    This live feed shows all institutional transactions in real time.

    View All

    SEC Form SC 13G/A filed by Medtronic plc. (Amendment)

    SC 13G/A - Medtronic plc (0001613103) (Subject)

    2/13/24 5:09:43 PM ET
    $MDT
    Biotechnology: Electromedical & Electrotherapeutic Apparatus
    Health Care

    SEC Form SC 13G/A filed by Medtronic plc. (Amendment)

    SC 13G/A - Medtronic plc (0001613103) (Subject)

    2/12/24 1:59:55 PM ET
    $MDT
    Biotechnology: Electromedical & Electrotherapeutic Apparatus
    Health Care

    SEC Form SC 13G/A filed by Medtronic plc. (Amendment)

    SC 13G/A - Medtronic plc (0001613103) (Subject)

    2/15/23 3:34:14 PM ET
    $MDT
    Biotechnology: Electromedical & Electrotherapeutic Apparatus
    Health Care

    $MDT
    Leadership Updates

    Live Leadership Updates

    View All

    Medtronic announces appointment of MiniMed chief financial officer ahead of intended separation into standalone company

    GALWAY, Ireland, July 8, 2025 /PRNewswire/ -- Medtronic plc (NYSE:MDT), a global leader in healthcare technology, today announced the appointment of Chad Spooner as chief financial officer (CFO) of MiniMed, in advance of its intended separation into a standalone, public company. Effective July 14, 2025, Chad will be responsible for overseeing the Finance function for Medtronic Diabetes and supporting initiatives aimed at accelerating profitable growth and delivering shareholder value as it prepares to become fully independent.  Chad brings over 25 years of financial leadership experience across healthcare, consumer, and industrial sectors. Most recently, he served as CFO at BIC (BB:PA), a pu

    7/8/25 8:45:00 AM ET
    $MDT
    Biotechnology: Electromedical & Electrotherapeutic Apparatus
    Health Care

    Medtronic Board appoints Dr. Joon Lee as a new director

    GALWAY, Ireland, June 23, 2025 /PRNewswire/ -- Medtronic plc (NYSE:MDT), a global leader in healthcare technology, today announced that its Board of Directors appointed Dr. Joon Lee, CEO at Emory Healthcare, Inc., to the Board as an independent director, effective June 18, 2025. Dr. Lee will serve on the Science and Technology Committee and Compensation and Talent Committee of the Board. "We are thrilled to welcome Dr. Lee, a highly respected interventional cardiologist and healthcare executive, to Medtronic's Board of Directors," said Geoff Martha, chairman and chief executive officer. "Dr. Lee brings deep expertise as a clinical researcher, academic leader, and physician executive with dec

    6/23/25 4:15:00 PM ET
    $MDT
    Biotechnology: Electromedical & Electrotherapeutic Apparatus
    Health Care

    Orchestra BioMed Reports Full Year 2024 Financial Results and Provides a Fourth Quarter Business Update

    NEW HOPE, Pa., March 31, 2025 (GLOBE NEWSWIRE) -- Orchestra BioMed Holdings, Inc. (NASDAQ:OBIO, "Orchestra BioMed" or the "Company")), a biomedical innovation company accelerating high-impact technologies to patients through risk-reward sharing partnerships, today reported its full year 2024 financial results and provided a fourth quarter business update. "We remain highly focused on execution of the BACKBEAT global pivotal study, which we believe has the potential to deliver landmark results that can establish AVIM therapy as a new standard of care for the treatment of uncontrolled hypertension in patients already indicated for a pacemaker. We also believe it can lay the foundation for

    3/31/25 4:21:30 PM ET
    $MDT
    $OBIO
    Biotechnology: Electromedical & Electrotherapeutic Apparatus
    Health Care
    Medicinal Chemicals and Botanical Products

    $MDT
    Financials

    Live finance-specific insights

    View All

    Medtronic announces cash dividend for fourth quarter of fiscal year 2026

    GALWAY, Ireland, March 5, 2026 /PRNewswire/ -- The board of directors of Medtronic plc (NYSE:MDT) on Thursday, March 5, 2026, approved the company's cash dividend for the fourth quarter of fiscal year 2026 of $0.71 per ordinary share. This quarterly declaration is consistent with the dividend increase announcement made by the company in May 2025. Medtronic is a constituent of the S&P 500 Dividend Aristocrats index, having increased its annual dividend payment for the past 48 consecutive years. The dividend is payable on April 17, 2026, to shareholders of record at the close of business on March 27, 2026.About MedtronicBold thinking. Bolder actions. We are Medtronic. Medtronic plc, headquarte

    3/5/26 4:53:00 PM ET
    $MDT
    Biotechnology: Electromedical & Electrotherapeutic Apparatus
    Health Care

    Medtronic reports strong third quarter fiscal 2026 results with highest enterprise revenue growth in 10 quarters

    Cardiovascular portfolio up 11% year-over-year; Cardiac Ablation Solutions grew 80% on strength of pulsed field ablation portfolioGALWAY, Ireland, Feb. 17, 2026 /CNW/ -- Medtronic plc (NYSE:MDT), a global leader in healthcare technology, today announced financial results for its third quarter (Q3) of fiscal year 2026 (FY26), which ended January 23, 2026.Q3 Key HighlightsRevenue of $9.0 billion, increased 8.7% as reported and 6.0% organic, 50 basis points ahead of Q3 guidanceGAAP diluted EPS of $0.89; non-GAAP diluted EPS of $1.36, three cents ahead of Q3 guidance mid-pointCompany reiterates FY26 organic revenue growth and EPS guidanceCardiac Ablation Solutions revenue increased 80%, includin

    2/17/26 6:45:00 AM ET
    $MDT
    Biotechnology: Electromedical & Electrotherapeutic Apparatus
    Health Care

    Medtronic announces cash dividend for third quarter of fiscal year 2026

    GALWAY, Ireland, Dec. 4, 2025 /PRNewswire/ -- The board of directors of Medtronic plc (NYSE:MDT) on Thursday, December 4, 2025, approved the company's cash dividend for the third quarter of fiscal year 2026 of $0.71 per ordinary share. This quarterly declaration is consistent with the dividend increase announcement made by the company in May 2025. Medtronic is a constituent of the S&P 500 Dividend Aristocrats index, having increased its annual dividend payment for the past 48 consecutive years. The dividend is payable on January 16, 2026, to shareholders of record at the close of business on December 26, 2025. About MedtronicBold thinking. Bolder actions. We are Medtronic. Medtronic plc, hea

    12/4/25 4:32:00 PM ET
    $MDT
    Biotechnology: Electromedical & Electrotherapeutic Apparatus
    Health Care